Screener
Revolution Medicines, Inc. RVMD EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Revolution Medicines, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Revolution Medicines, Inc.’s 10-Q, filed November 5, 2025. Open the filing →
- Filed
- Nov 5, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001193125-25-266923
FAQ
- What is Revolution Medicines, Inc.'s EBITDA margin?
- Revolution Medicines, Inc. (RVMD) reported EBITDA margin of -87,211.9% in Q3 2024.
- How has Revolution Medicines, Inc.'s EBITDA margin changed year-over-year?
- Revolution Medicines, Inc.'s EBITDA margin decreased by 6168.4% year-over-year, from -1,391.3% to -87,211.9%.
- What is the long-term trend for Revolution Medicines, Inc.'s EBITDA margin?
- Over 3 years (2020 to 2023), Revolution Medicines, Inc.'s EBITDA margin has grown at a 154.9% compound annual growth rate (CAGR), from -251.5% to -4,164.4%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Revolution Medicines, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude